The 2025 COVID wave and male fertility: What we're still learning…
Tired of too many ads? go ad free now
With the current wave, cases are steadily climbing in parts of India and beyond, and while the urgency has eased, new questions are still unfolding. Some of them are quieter, more long-term. One of those? Male infertility.
Fertility after COVID: A shift in the conversation
During the early waves of COVID-19, the emphasis was understandably on critical care and survival. But now, in 2025, with vaccines in place and the world far more prepared, we're seeing a different kind of concern emerge—not urgent, but steady and personal. People are beginning to ask: What has the virus left behind?
With this current wave, there's no widespread panic, but a quieter reckoning.
And for some men trying to conceive, that concern has turned toward reproductive health. At our fertility centres, we're seeing more men bring up questions around sperm health, especially after a recent COVID infection.
They're not alarmed, but they are curious. And science is starting to offer answers. Emerging research is beginning to unpack how COVID-19 affects the male reproductive system—temporarily in most cases, but significantly enough to merit a conversation.
This isn't about fear. It's about awareness. It's about giving people the space to ask what was once overlooked.Fertility may not be in the headlines anymore, but for many couples, it's very much top of mind.
The testes connection: What we know
COVID-19 enters the body through ACE2 receptors. These are found in the lungs, as well as in the testicles. That alone raised early concerns. Could the virus interfere with sperm development?
We still don't have all the answers, but research so far shows that in some men, especially those with moderate to severe illness, there are noticeable changes: lower sperm counts, reduced motility, and altered morphology.
Tired of too many ads? go ad free now
Sometimes all three. While similar changes can happen after any illness involving fever or inflammation, COVID-19 just happens to affect many systems at once, and on a large scale.
There's also growing evidence that inflammation and oxidative stress from the infection may alter the environment in which sperm form. Hormonal shifts could be playing a part too. These aren't necessarily long-term issues, but they do affect the body's rhythm, at least for a while.
Does it all bounce back?
In many cases, yes. Most men recover their baseline sperm health within a few months. But that window can feel long when time is precious, especially for couples already facing fertility challenges. There's also no universal timeline. Everyone's recovery looks a little different.
That's part of the complexity: the virus behaves differently from one person to the next. So does the recovery.
What you can do if you're concerned
If COVID is in your recent medical history and conception isn't happening as expected, you're not overthinking it.
• Semen testing is straightforward and can uncover key fertility indicators. It's non-invasive and might be the quickest way to know whether your system is still recalibrating or if something else is at play.
• It's also worth checking in with a doctor. Not because you should be alarmed, but because informed decisions tend to be better ones.
• While science looks at viral effects, the basics still count. What you eat, how you sleep, and how you manage stress are things that continue to shape hormone balance and sperm quality.
• Avoiding tobacco, limiting alcohol, and reducing heat exposure around the groin are all practical ways to support recovery.
Fertility conversations are evolving
Male fertility has long stayed in the background and has often been pushed to the woman's corner due to factors such as societal stigma, fear, lack of awareness, etc. But that's changing. More men are booking evaluations, asking questions, and showing up alongside their partners.
Whether COVID-19 has a short or long-term impact on male fertility, one thing's clear - being informed makes a difference. It's personal, it's emotional, and it's almost never linear—but fertility is something both partners can face and take charge of, together.
And awareness can offer something many couples need most - peace of mind.
(By Dr. Lavanya, Fertility Specialist, Nova IVF Fertility, Sarjapur, Bengaluru)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
From ouch to opportunity: India chases instant relief as pain market swells to Rs 16,000 crore; 5 brands pop up every week
India's pain relieving market is soaring, as more and more people are rushing to use over-the-counter (OTC) pills, sprays and creams to soothe everyday aches and pains. According to Nielsen data cited by industry executives, in the past five years, the segment has grown by more than a billion dollars, becoming the largest category within the non-prescription space. Since the onset of the pandemic, around five new pain relief brands have been launched each week on average, as per an ET report. In 2020, there were 1,552 brands catering to pain relief, including household names such as Volini, Omnigel, Dolo and Saridon. That figure has now soared to 2,771. Consumers are prioritising quick relief, said Shivam Puri, managing director at Cipla Health, 'Rise of urbanisation and increase in chronic illnesses have led to the need for faster, more convenient formats that are accessible across platforms,' Puri told ET. This rising demand comes despite continued warnings from healthcare professionals about the risks of indiscriminate painkiller use. Explosive growth The pain relief segment, particularly in urban markets, is largely driven by lifestyle factors such as gym injuries and sports-related strains. As a result, the combined market for analgesics and rubefacients has more than doubled, from Rs 6,820 crore in May 2020 to Rs 15,905 crore in May 2025, representing a compound annual growth rate (CAGR) of 18%. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Many Are Watching Tariffs - Few Are Watching What Nvidia Just Launched Seeking Alpha Read More Undo This is three times faster than the broader OTC market, which has grown at 6% CAGR to reach Rs 80,000 crore. Analgesics account for 75% of the pain management medication category. Paracetamol remains the dominant contributor, as per data from PharmaTrac, cited by ET. Sandeep Verma, who heads Bayer Pharmaceuticals' consumer health business for South Asia, noted a shift in perception since the Covid-19 outbreak. 'A lot of Indians view taking pain relief medication as a sign of weakness or worry about becoming dependent on it. Covid made many of us more aware of how stress, exhaustion, and even mild but recurring pain can chip away at our wellbeing and productivity,' he was quotde as saying. From chronic pain to lifestyle ailments Experts say that pain medications are being increasingly used to treat a wider range of issues, including inflammation and adjacent issues, leading to growing demand for pills. 'The analgesic segment that is dominated by paracetamols has been growing at a steady rate of 10%. This is because paracetamol medications are taken alongside other conditions that could include arthritis, any other bacterial or viral infection,' Sheetal Sapale, vice president, commercial, at PharmaTrac was quoted as saying. Nitin Kumar Sinha, consultant physician at WeCare Wellness in Mumbai, attributed the trend to rising lifestyle-related ailments. 'Lack of physical exercise, increase in body weight leading to knee and joint pain, anxiety, depression are all causes of increase in body pain, headaches or migraine,' he told ET. He also warned that self-medication is on the rise which can have serious consequences if used over a prolonged period of time, such as damage to the kidneys. IPCA's Zerodol SP, Janssen's Ultracet, GSK's Calpol, Micro Lab's Dolo, Torrent's Chymoral Forte and Cipla's Ibugesic Plus, are one of the top selling drugs. Most of these are prescription medications. Skin creams, allergies also see rise in OTC demand Pain relief isn't the only area where Indians are increasingly self-medicating. The demand for dermatological creams, traditionally prescribed by dermatologists, is also surging, particularly among Gen Z consumers. Bhanu Prakash, partner and healthcare services industry leader at Grant Thornton, said, 'Over-the-counter as a segment has grown post-Covid because of more knowledge and information for categories including anti-allergic medications, skin creams, tear drops among others.' Derma products, which are used to treat issues related to the skin and scalp, are now the second-largest non-prescription category after pain, expanding at a CAGR of 8% over the last five years, to become a Rs 14,854 crore market. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
The Print
4 hours ago
- The Print
AI can help build a healthier world. Here is how
As the world was still reeling from COVID-19, an outbreak of Mpox struck the globe from 2022 to 2023. The outbreaks were first seen in remote mining communities and last-mile villages in the Democratic Republic of Congo (DRC) and then spread to neighbouring countries. This resulted in a historically rare disease spreading widely outside its endemic regions to Europe and Asia. Mpox is highly virulent and can be fatal. The regions where the disease is endemic see overlapping challenges of conflict, changing weather patterns and population displacement, intersecting with limited infrastructure and health personnel. In DRC and neighbouring regions that see continued outbreaks, rapid testing for Mpox within communities and at borders was and still is critical to maintain global health security. How AI helps stem the spread of Mpox This is where a new ally joined this fight: artificial intelligence (AI). In Rwanda, we collaborated with the government to develop and deploy an Mpox skin image detection AI tool, enabling health workers to use mobile devices at key border entry points with Uganda, Burundi and the DRC. The AI skin test complements molecular screening methods to drive early detection, outbreak control and protection of vulnerable groups at risk of serious Mpox cases. Show Full Article Teaching an algorithm to screen and support surveillance is transferable to other infectious diseases, tailored to contexts and populations. Global Fund-financed countries have deployed AI since 2018 through health ministries and communities to expand healthcare access, increase testing volumes and guide health workers to where their work is most needed to manage tuberculosis. This existing base can be expanded, at a reasonable cost, to screen for other infectious diseases too. For this next era of AI innovation, the Global Fund and other multilaterals must balance the push to deploy cost-effective AI tools across the health sector, while maintaining investment in good, secure digital foundations. Health systems operate across the care continuum from diagnosis to supporting triage and treatment to decision-support, even in countries where there is finite human and infrastructural capacity. As artificial intelligence reshapes every industry, the Global Fund works with countries to ask critical questions relevant to the health sector: What are the challenges we are facing? Which AI applications make sense today? How can they be deployed to accelerate progress? How can they be scaled? The answers lie in a clear theory of change. By adopting new technologies, countries have successfully aligned innovations to their digital maturity and financial readiness, advancing in step with their capacity, rather than waiting for the 'perfect' foundations or leaping too far ahead. Pilots need to be embedded in national health platforms AI tools must be designed for scale, meaning moving beyond single-use apps towards modular, open-architecture platforms. From the start, pilots should be embedded within health ministries or national digital-health platforms and built with interoperable components that can be adapted for new diseases, geographies, or functions. For this vision to be realized, we must continue investing in the foundations of quality data and digital systems. We hold AI tools to the same rigorous standards and accountability frameworks that guide other health investments, supporting countries in adopting tools that are tailored to their existing systems and maturity. While AI has incredible potential, it is also a completely new way of operating that needs to be introduced through secure, reasoned, ethical, evidence-based scaling. Countries with basic digital infrastructure – such as reliable power, health facility-level connectivity and digitized patient registers – can already implement simple AI tools. These include: triage chatbots, dashboard stock-out alerts or AI-driven text message reminders. As the digital systems of a country mature, more advanced applications can be deployed, such as predictive surveillance, automated image diagnostics and optimized healthcare administration and workforce productivity apps. Countries further along the maturity curve – with interoperable national health information exchanges, stable broadband and maintenance budgets – can consider advanced analytics, such as real-time outbreak forecasting or precision resource allocation models. AI must be adopted at a pace that can be sustained and scaled This staged approach ensures each country advances in its use of AI at a pace it can sustain and scale; the availability of a robust basic digital infrastructure is what enables Rwanda to use its Mpox skin image detection AI tool. Despite the obvious benefits of these investments, lower-income countries face high borrowing costs and constrained budgets. Concessional financing and grants from multilaterals can be supported by mobilizing pooled funds, securing preferential pricing on hardware and software and aligning institutional financing with national digital-health strategies and data standards. By underwriting shared infrastructure, such as solar-powered servers, regional analytics hubs or last-mile networks, these institutions absorb much of the initial risk, giving countries the runway they need to integrate AI into public systems, without shouldering the full financial burden up front. Of course, these must enable countries to take clear ownership and facilitate full sustainability, regardless of the initial funding source. To harness the power of AI for global health, institutional funders and governments can adopt these four key principles: 1. Assess readiness against maturity Evaluate every AI proposal based on where a given country sits on digital maturity and financial readiness curves. 2. Phase ambition Match the complexity of AI use cases to maturity levels. Start with simple tools, then extend to advanced AI as systems and budgets strengthen. 3. Mandate public–private co-investment The major AI innovations are driven by the private sector. Design funding so that governments, multilateral funding institutions and private partners share costs, expertise and risk and operate in a functional and sustainable digital marketplace. 4. Plan for ownership at each stage Define clear handover roadmaps that guide the transition from pilot to scaled platform, aligned with each phase of maturity. When AI adoption matches a country's evolving capacity and when multilateral funders convene all actors to share risk and build shared infrastructure, we unlock technology's true promise: smarter, more equitable health systems that can both end major diseases and endure. It's time to move beyond novelty towards solutions that work at scale and leave no one behind. This article is republished from The World Economic Forum under a Creative Commons license. Read the original article.
Time of India
6 hours ago
- Time of India
Pfizer COVID vaccine may cause serious eye damage, new study reveals
A recent study has raised concerns that the Pfizer-BioNTech COVID-19 vaccine may cause subtle but potentially serious effects on the eye's cornea, particularly its innermost layer, the endothelium. Conducted by scientists in Turkey and published in the journal Ophthalmic Epidemiology, the research examined changes in the corneas of 64 patients before and after receiving both doses of the vaccine. While no immediate vision loss was reported, the study found that the vaccine led to thicker corneas, a reduced number of endothelial cells, and structural changes that could affect eye health over time. According to the Daily Mail, experts caution that while these changes may be harmless in the short term, they could pose risks for those with pre-existing eye conditions or corneal transplants. Pfizer COVID vaccine linked to corneal cell loss, swelling and altered structure Researchers found that the average thickness of the cornea increased from 528 to 542 micrometers after two Pfizer doses, a roughly 2 percent rise. The endothelial cell count, responsible for keeping the cornea clear, dropped by about 8 percent, from 2,597 to 2,378 cells per square millimeter. Though this remains within a safe range for healthy individuals, such a decline could pose serious risks for those with a low baseline count due to aging, eye surgeries, or diseases like Fuchs' dystrophy. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hear better, live easier Amplifon Book Now Undo In addition, the study noted an increase in cell size variation (coefficient of variation), rising from 39 to 42, suggesting the corneal endothelium was under stress. The number of cells maintaining a healthy hexagonal shape also dropped from 50 percent to 48 percent. As Daily Mail reported, these signs may not immediately affect vision but could compromise the cornea's long-term clarity and function if they persist. Scientists urge caution but do not oppose vaccination The study, which analyzed 128 eyes using Sirius corneal topography and Tomey EM-4000 specular microscopy, does not recommend halting vaccination efforts. Rather, it calls for ongoing monitoring of corneal health in individuals with known eye vulnerabilities. The researchers emphasized that the changes observed might be temporary responses to stress or inflammation and could resolve over time. Still, they warned that 'the endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft,' especially if future studies confirm long-term damage. According to Daily Mail, this adds to existing concerns over rare side effects of mRNA vaccines, including myocarditis and pericarditis, particularly in younger men. The researchers plan to continue tracking participants to determine if these early corneal changes progress or stabilize over time.
